Cargando…

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

Accumulating evidence highlights natural killer (NK) cell parameters as potential prognostic factors in cancer patients, which provides a strong rationale for developing therapeutic strategies aiming at restoring NK cell. However, reaching this point warrants better characterization of tumor-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Chretien, Anne-Sophie, Fauriat, Cyril, Orlanducci, Florence, Galseran, Claire, Rey, Jerome, Bouvier Borg, Gaelle, Gautherot, Emmanuel, Granjeaud, Samuel, Hamel-Broza, Jean-François, Demerle, Clemence, Ifrah, Norbert, Lacombe, Catherine, Cornillet-Lefebvre, Pascale, Delaunay, Jacques, Toubert, Antoine, Gregori, Emilie, Luche, Herve, Malissen, Marie, Arnoulet, Christine, Nunes, Jacques A., Vey, Norbert, Olive, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447002/
https://www.ncbi.nlm.nih.gov/pubmed/28611767
http://dx.doi.org/10.3389/fimmu.2017.00573
_version_ 1783239214414954496
author Chretien, Anne-Sophie
Fauriat, Cyril
Orlanducci, Florence
Galseran, Claire
Rey, Jerome
Bouvier Borg, Gaelle
Gautherot, Emmanuel
Granjeaud, Samuel
Hamel-Broza, Jean-François
Demerle, Clemence
Ifrah, Norbert
Lacombe, Catherine
Cornillet-Lefebvre, Pascale
Delaunay, Jacques
Toubert, Antoine
Gregori, Emilie
Luche, Herve
Malissen, Marie
Arnoulet, Christine
Nunes, Jacques A.
Vey, Norbert
Olive, Daniel
author_facet Chretien, Anne-Sophie
Fauriat, Cyril
Orlanducci, Florence
Galseran, Claire
Rey, Jerome
Bouvier Borg, Gaelle
Gautherot, Emmanuel
Granjeaud, Samuel
Hamel-Broza, Jean-François
Demerle, Clemence
Ifrah, Norbert
Lacombe, Catherine
Cornillet-Lefebvre, Pascale
Delaunay, Jacques
Toubert, Antoine
Gregori, Emilie
Luche, Herve
Malissen, Marie
Arnoulet, Christine
Nunes, Jacques A.
Vey, Norbert
Olive, Daniel
author_sort Chretien, Anne-Sophie
collection PubMed
description Accumulating evidence highlights natural killer (NK) cell parameters as potential prognostic factors in cancer patients, which provides a strong rationale for developing therapeutic strategies aiming at restoring NK cell. However, reaching this point warrants better characterization of tumor-induced NK cell alterations. Our group recently reported heterogeneous NK maturation in acute myeloid leukemia (AML) patients. However, the clinical significance of such observations remained to be assessed on a larger cohort of patients. NK maturation based on expression of CD56, CD57, and KIR was assessed by flow cytometry in newly diagnosed AML patients (N = 87 patients from GOELAMS-LAM-IR-2006 multicenter trial). Clinical outcome was evaluated with regard to NK maturation profiles. Unsupervised integrated analysis of NK maturation markers confirmed the existence of three distinct groups of patients [hypomaturation (24.1%), intermediate maturation (66.7%), and hypermaturation (9.2%)]. In univariate analysis, significant differences in overall survival (OS) (P = 0.0006) and relapse-free survival (RFS) (P < 0.0001) were observed among these different groups. Patients with hypomaturation profile had reduced OS, with 3-year OS rates of 12.5 vs 57.1 and 57.4% for patients with intermediate and hypermaturation, respectively. Consistently, patients with hypomaturation profile had reduced RFS, with 3-year RFS rates of 0 vs 52.6 and 73.3% for patients with intermediate and hypermaturation, respectively. In multivariate Cox regression models, NK hypomaturation remained significantly associated with reduced OS and RFS, independent of other factors [hazard ratio (HR) = 4.15, P = 0.004 and HR = 8.23, P = 0.003, respectively]. NK maturation defects were further explored by mass cytometry and revealed that NK hypomaturation profile is associated with a reduced frequency of memory-like NK cells. In conclusion, besides classical alterations of NK triggering and inhibitory receptors expression in AML, we confirm that the homeostasis of NK maturation can be modified in the context of AML, notably with a deep maturation blockade in almost 10% patients.
format Online
Article
Text
id pubmed-5447002
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54470022017-06-13 Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia Chretien, Anne-Sophie Fauriat, Cyril Orlanducci, Florence Galseran, Claire Rey, Jerome Bouvier Borg, Gaelle Gautherot, Emmanuel Granjeaud, Samuel Hamel-Broza, Jean-François Demerle, Clemence Ifrah, Norbert Lacombe, Catherine Cornillet-Lefebvre, Pascale Delaunay, Jacques Toubert, Antoine Gregori, Emilie Luche, Herve Malissen, Marie Arnoulet, Christine Nunes, Jacques A. Vey, Norbert Olive, Daniel Front Immunol Immunology Accumulating evidence highlights natural killer (NK) cell parameters as potential prognostic factors in cancer patients, which provides a strong rationale for developing therapeutic strategies aiming at restoring NK cell. However, reaching this point warrants better characterization of tumor-induced NK cell alterations. Our group recently reported heterogeneous NK maturation in acute myeloid leukemia (AML) patients. However, the clinical significance of such observations remained to be assessed on a larger cohort of patients. NK maturation based on expression of CD56, CD57, and KIR was assessed by flow cytometry in newly diagnosed AML patients (N = 87 patients from GOELAMS-LAM-IR-2006 multicenter trial). Clinical outcome was evaluated with regard to NK maturation profiles. Unsupervised integrated analysis of NK maturation markers confirmed the existence of three distinct groups of patients [hypomaturation (24.1%), intermediate maturation (66.7%), and hypermaturation (9.2%)]. In univariate analysis, significant differences in overall survival (OS) (P = 0.0006) and relapse-free survival (RFS) (P < 0.0001) were observed among these different groups. Patients with hypomaturation profile had reduced OS, with 3-year OS rates of 12.5 vs 57.1 and 57.4% for patients with intermediate and hypermaturation, respectively. Consistently, patients with hypomaturation profile had reduced RFS, with 3-year RFS rates of 0 vs 52.6 and 73.3% for patients with intermediate and hypermaturation, respectively. In multivariate Cox regression models, NK hypomaturation remained significantly associated with reduced OS and RFS, independent of other factors [hazard ratio (HR) = 4.15, P = 0.004 and HR = 8.23, P = 0.003, respectively]. NK maturation defects were further explored by mass cytometry and revealed that NK hypomaturation profile is associated with a reduced frequency of memory-like NK cells. In conclusion, besides classical alterations of NK triggering and inhibitory receptors expression in AML, we confirm that the homeostasis of NK maturation can be modified in the context of AML, notably with a deep maturation blockade in almost 10% patients. Frontiers Media S.A. 2017-05-29 /pmc/articles/PMC5447002/ /pubmed/28611767 http://dx.doi.org/10.3389/fimmu.2017.00573 Text en Copyright © 2017 Chretien, Fauriat, Orlanducci, Galseran, Rey, Bouvier Borg, Gautherot, Granjeaud, Hamel-Broza, Demerle, Ifrah, Lacombe, Cornillet-Lefebvre, Delaunay, Toubert, Gregori, Luche, Malissen, Arnoulet, Nunes, Vey and Olive. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chretien, Anne-Sophie
Fauriat, Cyril
Orlanducci, Florence
Galseran, Claire
Rey, Jerome
Bouvier Borg, Gaelle
Gautherot, Emmanuel
Granjeaud, Samuel
Hamel-Broza, Jean-François
Demerle, Clemence
Ifrah, Norbert
Lacombe, Catherine
Cornillet-Lefebvre, Pascale
Delaunay, Jacques
Toubert, Antoine
Gregori, Emilie
Luche, Herve
Malissen, Marie
Arnoulet, Christine
Nunes, Jacques A.
Vey, Norbert
Olive, Daniel
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title_full Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title_fullStr Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title_full_unstemmed Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title_short Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
title_sort natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447002/
https://www.ncbi.nlm.nih.gov/pubmed/28611767
http://dx.doi.org/10.3389/fimmu.2017.00573
work_keys_str_mv AT chretienannesophie naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT fauriatcyril naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT orlanducciflorence naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT galseranclaire naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT reyjerome naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT bouvierborggaelle naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT gautherotemmanuel naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT granjeaudsamuel naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT hamelbrozajeanfrancois naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT demerleclemence naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT ifrahnorbert naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT lacombecatherine naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT cornilletlefebvrepascale naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT delaunayjacques naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT toubertantoine naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT gregoriemilie naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT lucheherve naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT malissenmarie naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT arnouletchristine naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT nunesjacquesa naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT veynorbert naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia
AT olivedaniel naturalkillerdefectivematurationisassociatedwithadverseclinicaloutcomeinpatientswithacutemyeloidleukemia